^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    NKG2D-CAR-NK92 cells

    i
    Other names: NKG2D-CAR-NK92 cells, NKG2D-CAR-NK92 Chimeric Antigen Receptor Modified NK92 Cells
    Associations

    News

    Trials
    Company:
    Xinxiang Medical University
    Drug class:
    NK cell stimulant
    Related drugs:
    Associations

    News

    Trials
    9ms
    NKG2D-CAR-NK92 Cells Immunotherapy for Solid Tumors (clinicaltrials.gov)
    P1, N=20, Recruiting, Xinxiang medical university | Trial completion date: Nov 2023 --> Nov 2025 | Trial primary completion date: Sep 2023 --> Sep 2025
    Trial completion date • Trial primary completion date
    |
    NKG2D-CAR-NK92 cells
    almost2years
    NKG2D-CAR-NK92 Cells Immunotherapy for Solid Tumors (clinicaltrials.gov)
    P1, N=20, Recruiting, Xinxiang medical university | Initiation date: Sep 2022 --> Jan 2023
    Trial initiation date
    |
    NKG2D (killer cell lectin like receptor K1)
    |
    NKG2D-CAR-NK92 cells
    2years
    NKG2D-CAR-NK92 Cells Immunotherapy for Solid Tumors (clinicaltrials.gov)
    P1, N=20, Recruiting, Xinxiang medical university
    New P1 trial
    |
    NKG2D (killer cell lectin like receptor K1)
    |
    NKG2D-CAR-NK92 cells